Our data demonstrated that both EGFR and HER2 are important targets for hCAP18/LL-37 in HCC, resulting from overexpression of hCAP18/LL-37 significantly activating phosphorylation of both EGFR and HER2 in cultured HCC cells and xenograft tumors. The gene discussed is CAMP; the disease is hepatocellular carcinoma.